BioSpace News Archive

Blue Earth Diagnostics Ltd, a Bracco company and recognised leader in the development and commercialisation of innovative PET radiopharmaceuticals, announced that it has signed an exclusive strategic agreement with Sinotau Pharmaceutical Group for the positron emission tomography imaging agent flotufolastat injection in prostate cancer.

IDEAYA Biosciences, Inc. announces the publication of the abstract for a proffered paper session at the European Society of Medical Oncology Congress 2023 relating to selected clinical data from the company’s ongoing Phase 2 clinical trial evaluating darovasertib in combination with crizotinib in patients having metastatic uveal melanoma.

Antion Biosciences SA (Antion), an innovative developer of cell and gene therapy technologies, is delighted to announce the presentation of two posters at the upcoming ESGCT Annual Meeting on 24-27 October 2023, in Brussels, Belgium.

Monte Rosa Therapeutics, a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced interim data from the Phase 1 dose escalation part of its ongoing Phase 1/2 open-label, multicenter study of MRT-2359 in patients with MYC-driven solid tumors, including lung cancers and high-grade neuroendocrine cancer.

Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced it has entered into a strategic collaboration and licensing agreement with global healthcare leader Roche to discover and develop MGDs against targets in cancer and neurological diseases previously considered impossible to drug.

RadNet, Inc. announced that it will host a conference call to discuss its third quarter 2023 financial results on Thursday, November 9th, 2023 at 7:30 a.m. Pacific Time.

Basilea Pharmaceutica Ltd, Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced that scientific presentations with new data on its antibiotic ceftobiprole have been presented at Infectious Disease Week 2023, highlighting its utility for the treatment of severe bacterial infections.

Zealand Pharma A/S announced presentations of clinical and non-clinical results for Zealand’s amylin analog ZP8396 at the Obesity Society Annual Meeting being held in Dallas, Texas from October 14-17, 2023.

Diamyd Medical is hosting a webcast presentation on October 20th at 2:00 pm CET / 8:00 am EDT with Ulf Hannelius, CEO of Diamyd Medical, Josh Vieth, Director of Research at JDRF, as well as Mark Atkinson, Director for the University of Florida Diabetes Institute and member of the Board of Directors of Diamyd Medical.

Diakonos Oncology Corporation, a clinical stage immuno-oncology company, announced that the U.S. Food and Drug Administration has granted Fast Track designation for the Company’s unique dendritic cell vaccine, DOC1021.